In-Stent Restenosis Post-Approval Study

NACompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2021

Conditions
Peripheral Artery DiseaseVascular Disease
Interventions
DEVICE

Gore VIABAHN Endoprosthesis

Trial Locations (23)

10016

New York University Langone Medical Center, New York

10065

New York Presbyterian Hospital/Weill Cornell Medical Center, New York

16502

St. Vincent's Consultants in Cardiovascular Disease, Erie

25304

Charleston Area Medical Center, Charleston

27607

North Carolina Heart and Vascular, Raleigh

29615

Greenville Hospital System, Greenville

33140

Mount Sinai Medical Center, Miami

48602

Covenant Medical Center, Inc., Saginaw

49684

Munson Medical Center, Traverse City

52242

University of Iowa Hospitals and Clinics, Iowa City

58122

Sanford Health, Fargo

61107

Rockford CardioVascular Associates, Rockford

64116

Midwest Aortic and Vascular Institute (MAVI), North Kansas City

70360

Cardiovascular Institute of the South, Houma

75093

Texas Health Research - Presbyterian Hospital of Plano, Plano

75231

Texas Health Research - Presbyterian Heart and Vascular, Dallas

96819

Kaiser Foundation Hospital, Honolulu

97225

Providence Heart Clinic, Portland

98122

Swedish Medical Center - Heart and Vascular Research, Seattle

02906

The Miriam Hospital, Providence

Unknown

Klinikum Rosenheim, Rosenheim

Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia

Skånes Universitetssjukhus, Malmo

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY

NCT02542267 - In-Stent Restenosis Post-Approval Study | Biotech Hunter | Biotech Hunter